CDSCO Panel Grants Novartis Protocol Amendment For Ofatumumab Dr. Divya Colin31 Dec 2023 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis Gets CDSCO Panel Nod to study Iptacopan Dr. Divya Colin23 Dec 2023 6:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Novartis, the Subject Expert Committee (SEC) functional under the Central Drug...
JB Pharma enters Opthalmology space, signs Rs 1,089 crore deal with Novartis for 10 brands Ruchika Sharma20 Dec 2023 11:14 AM ISTNew Delhi: JB Chemicals & Pharmaceuticals Ltd (JB Pharma) has announced that the Company has inked a trade mark licence agreement along with...
FDA approves Fabhalta as oral treatment for paroxysmal nocturnal hemoglobinuria Jacinthlyn Sylvia11 Dec 2023 11:15 AM ISTThe US Food and Drug Administration has approved Fabhalta (iptacopan) as first oral monotherapy for adults suffering from paroxysmal nocturnal...
Novartis Gets CDSCO Panel Nod to study Remibrutinib to treat chronic spontaneous urticaria Dr. Divya Colin8 Dec 2023 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis gets USFDA nod for Fabhalta for adults with paroxysmal nocturnal hemoglobinuria Ruchika Sharma7 Dec 2023 11:43 AM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Fabhalta (iptacopan) as the first oral monotherapy for the...
Novartis raises sales growth target to 5 percent a year through 2027 Ruchika Sharma28 Nov 2023 3:30 PM ISTFrankfurt: Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of...
Atrasentan found superior to placebo for proteinuria reduction in the Phase 3 Trial for IgA Nephropathy. Dr Kartikeya Kohli4 Nov 2023 11:15 AM ISTIgA nephropathy (IgAN) is an autoimmune disorder wherein clusters of antibodies get deposited in the kidneys, leading to inflammation and damage to...
Novartis wins USFDA nod for Cosentyx to treat hidradenitis suppurativa in adults Ruchika Sharma1 Nov 2023 2:00 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe...
CDSCO Panel approves Novartis proposal to update package insert of Secukinumab Dr. Divya Colin25 Oct 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Center Drug Standard Control Organisation (CDSCO) has granted approval to drug...
FDA approves intravenous Secukinumab for Rheumatic diseases Dr. Kamal Kant Kohli11 Oct 2023 11:45 AM ISTThe US Food and Drug Administration (FDA) has approved an intravenous formulation of Secukinumab for patients with psoriatic arthritis, ankylosing...
Novartis Cosentyx IV formulation for rheumatic diseases bags USFDA okay Ruchika Sharma10 Oct 2023 1:30 PM ISTThe IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.
